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Tumor-Initiating and Promoting Activities of
Di(2-ethylhexyl) Phthalate in Vivo and in
Vitro
by J. M. Ward,* B. A. Diwan,* M. Ohshima,* H. Hu,*
H. M. Schuller,*t and J. M. Rice*
The carcinogenic effects ofdi(2-ethylhexyl) phthalate (DEHP), including its potential as an initiator and
as a promoter ofcarcinogenesis, were studied in mouse liver and skin and in rat liver in vivo, and in mouse
epidermis-derived JB6 cells in vitro. A mouse model for liver initiation and promotion involved initiation by
injection ofN-nitrosodiethylamine (DEN)intraperitoneally intomaleB6C3F1 miceat4weeksofage, followed
by exposure to either DEHP in the diet (3000, 6000, or 12,000 ppm) or phenobarbital in the drinking water
(500 ppm), beginning 1 to 2 weeks later and continuing for periods offrom 1 day to 18 months. Female F344/
NCr rats were subjected to a similar protocol in which promotion continued for 14 weeks. DEHP promoted
focal hepatocellular proliferative lesions (FHPL), including hyperplastic foci and neoplasms initiated by
DEN in mice but not in rats. Skin-painting studies in female CD-1 or SENCAR mice involved initiation by
a single topical exposure to 7,12-dimethylbenz[aI-anthracene (DMBA) applied to the dorsal skin, followed by
repeated percutaneous exposure to a tumor promoter, either DEHP or 12-O-tetradecanoylphorbol-13-acetate
(TPA). To test for two-stage skin tumor promotion, SENCAR mice were initiated with DMBA and then TPA
was administered for only 2 weeks, after which DEHP was subsequently administered for 26 weeks. DEHP
displayed very weak complete promoting activity and definite second stage promoting activity in SENCAR
mouse skin, but was inactive under our conditions on CD-1 mouse skin. In vitropromoting activity ofDEHP
and its hydrolysis products, mono(2-ethylhexyl) phthalate (MEHP) and 2-ethylhexanol (EH), was studied
by using promotable mouse epidermis-derived JB6 cells. DEHP and MEHP promotedJB6 cells to anchorage
independence, while EH did not.
Introduction
Di(2-ethylhexyl) phthalate (DEHP), a plasticizer and
hepatic peroxisome proliferator (1-3), was found to be
carcinogenic in U.S. National Toxicology Program car-
cinogenesis bioassays (4), in which it increased the in-
cidence of hepatocellular neoplasms in F344 rats and in
B6C3F1 mice. Because DEHP was demonstrated to have
no genotoxic activity in bacterial mutagenesis assays or
in other in vitro assays (4,5), the hypothesis was tenable
that this compound achieved its biologic effects by acting
as a tumor promoter, enhancing the development of nat-
urally occurring or chemically induced hepatocellular tu-
mors ofrats or mice. We have used an in vivo model for
liver tumor initiation and promotion in mice that utilizes
N-nitrosodiethylamine (DEN) as an initiatorin weanling
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B6C3F1 males (6,7), and have adapted the same protocol
to weanling female F344 rats. With these systems, we
havetested DEHPasapotentialinitiatorofandpromoter
for hepatocellular tumors in vivo.
Atleast inthe mouse skin system, the promotion stage
has empirically been subdivided into two distinct com-
ponents, stage I and stage II, which are qualitatively
differentfrominitiation and from each other(8-10). Mez-
erein is only a weak complete promoter, but when given
repeatedly (two times per week) after limited exposure
to TPA, it induces asignificant tumorresponse in adose-
dependent manner (9). To investigate whether DEHP
acts as atumorinitiatoror as acomplete or second-stage
tumor promoter in mouse skin, we used an in vivo assay
utilizing CD-1 and SENCAR mice.
There arefewinvitroassaysfortumorpromoters, and
only one that is predictive of target cell specificity in
vivo. This, one ofthe best characterized cell culture as-
says, was originally developed to study phorbol esters,
and is based on induction by certain substances oftrans-
formation ofmouse epidermis-derived JB6 cell lines to a
neoplastic phenotype, characterized by anchorage inde-WARD ET AL.
pendence and tumorigenicity (11). Using this system, we
tested the promoting abilities of DEHP and its major
hydrolysis products, mono(2-ethylhexyl) phthalate
(MEHP) and 2-ethylhexanol (EH).
We report that DEHP promotes but appears not to
initiate neoplasia in mouse hepatocytes and mouse skin
invivo and promotes transformationofJB6cellsinvitro,
and that MEHP but not EH promotesJB6 cells invitro.
Materials and Methods
Chemicals
The following chemicals were purchased: DEN (Sigma
Chemical Co., St. Louis, MO, USA), DEHP (Aldrich
Chemical Co., Milwaukee, WI, USA), EH (Aldrich
Chemical Co., Milwaukee, WI, USA), dimethylbenz-
anthracene (DMBA) (Eastman Kodak Co., Rochester,
NY), and TPA (C.C.R. Inc., Eden Prarie, MN). DEHP
was analyzed by GLC by Dr. Gary Muschik (Program
Resources Inc., FCRF, Frederick, MD, USA) and found
to be 99% pure. MEHPwas synthesized by aslight mod-
ification of the method described by Kenyon and Platt
(12), and was analyzed by FID/GLC and found to be 96%
pure. For in vitro assays, DEHP was mixed with ace-
tone, while MEHP and EH were dissolved in DMSO.
Tumor Initiation, Promotion, and
Carcinogenicity in Mouse Liver
An initiation-promotion system for male B6C3F1
mouse liver previously described by us was used (6). In
brief, weanlingmale B6C3F1 miceobtained fromthe NCI
Division ofCancerTreatment, Animal Genetics and Pro-
duction Program, Frederick, MD, were injected once
intraperitoneally at 4 weeks of age with DEN in trica-
prylin solution at a dose of 80 mg/kg body weight. Two
weeks later mice were placed on diets containing DEHP
at 12,000, 6000 or 3000 ppm or given water containing
PB at 500 ppm. Appropriate controls were included (Ta-
bles 1 and 2). At 2, 4, 6, 8, 10, or 18 months, groups of
mice were killed. At selected time periods, hepatic DNA
synthesis and mitotic indices ofhepatocytes were meas-
ured in groups of four to six mice. Tritiated thymidine
wasinjectedintraperitoneally (2 ,Ci/gbodyweightevery
30 min for sixinjections) and mice were sacrificed 30 min
after the last injection.
To test for initiating activity by DEHP, mice received
one intragastric dose (25 or 50 g/kg) at 4 weeks of age
followedbyphenobarbital (PB)continuouslyfrom6weeks
of age. Mice were killed at 6 and 18 months.
DEHP as a Tumor Promoter in Rat Liver
Female F344/NCr rats in groups of10, 5 weeks ofage,
wereinjectedintraperitoneallywithN-nitrosodiethylam-
ine in tricaprylin at a dose of 282 mg/kg. Two weeks
later, rats were placed on diets containing 12,000 ppm
DEHP or on drinking water containing PB at 500 ppm.
After 14 weeks of exposure to the promoter, rats were
sacrificed and eight liver sections (two per lobe) were
fixed in formalin for histology or in cold 95% ethanol for
gamma glutamyl transpeptidase (GGT) histochemistry
Effectiveness of DEHP and PB as Liver
Tumor Promoters after Short-Term
Exposure in B6C3F1 Mice
In a more recent experiment, DEHP was fed in the
diet at 3000 ppm, or PB was given in the water at 500
ppm for 1, 7, 28, 84, or 168 days, beginning one week
after DEN injection at 4 weeks ofage (7). All mice were
killed at 168 days. Additional groups received DEHP or
PB for 168 days and were killed 84 days later to observe
possible regression of hepatic proliferative lesions.
Pathology
A complete necropsy was performed on all mice. The
liver was weighed and examined carefully for gross le-
sions. Two representative sections were prepared from
each lobe (eight sections permouse) and fixed in formalin
for computerized image analysis ofhepatic lesions. Focal
hepatocellular proliferative lesions (FHPL) included hy-
perplasticfoci, adenomas, and carcinomasand wereclass-
ified by staining properties to distinguish those that had
clearoreosinophilic cytoplasmfromthosewithbasophilic
cytoplasm (6,13). Avidin-biotin peroxidase complex im-
munocytochemistry was used to localize mouse a-feto-
protein to hepatocytes (6). The mean number of FHPL
per square or cubic centimeters ofliver, and mean areas
and volumes of FHPL were determined using an auto-
mated system (Videoplan, Zeiss, Inc., New York, NY)
and Zeiss stereology software. Appropriate statistical
analyses were performed (6). Portions of23 liver nodules
were transplanted to the mammary fat pad ofweanling
male B6C3F1 mice. Quantitative electron microscopic
analysis for cytoplasmic peroxisomes, mitochondria, and
roughand smoothendoplasmicreticulum, cellandnuclear
cross-sectionalareas andnuclear/cytoplasmic ratioswere
performed on representative liver samples fixed in cold
glutaraldehyde from normal untreated mice and from
mice treated with DEHP or PB, and on liver tumors in
mice given DEN followed by DEHP or PB (14).
Skin Initiation-Promotion Studies
CD-1 mice initiated by a single topical application of
50 ,ug DMBA to the dorsal skin received DEHP (98.1 ,ug
in acetone, 0.2 mL total volume) or TPA (10 ,ug in 0.2
mL acetone) twice weekly for 40 weeks in a routine skin
initiation-promotion protocol (15). Mice were killed at 40
weeks. To test for second-stage promoting activity, fe-
male SENCAR mice were given DMBA once (20 ,ug), and
then TPA (2 jig, twice a week for 2 weeks), followed by
DEHP (100 jig, twice weekly), or by TPA, mezerein or
acetone weekly for up to 26 weeks (15). To test for com-
plete promoting activity by DEHP in SENCAR mice,
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Table 1. Promoting activity of DEHP and PB.'
Treatment No. of mice with
Effective no. of Mean survival, Hepatocellular Pulmonary
Initiator, mg/kg Promoter, ppm mice months FHPL, % carcinoma, % metastases, %
DEN None 10 >18 9(90)* 3(0) 0
DEN (80) DEHP (3000) 10 >18 10(100)* 10(100) 2(20)
DEN (80) DEHP (6000) 20 >17 20(100)* 18(90) 5(25)
DEN (80) DEHP (12000) 20 8.7 20(100)* 11(55) 2(10)
None DEHP (3000) 10 >18 5(50)* 1(10) 0
None DEHP (6000) 10 >18 3(30) 1(10) 0
None DEHP (12000) 10 8.4 0 0 0
DEN (80) PB (500) 20 >14.8 20(100)* 15(75) 3(15)
None PB (500) 17 >18 13(76)* 3(17) 0
None None 10 >18 0 0 0
aMale B6C3F1 mice, 4 weeks of age, were injected intraperitoneally with DEN in tricaprylin at a dosage of 80 mg/kg. Two weeks later,
they were given the promoter for up to 18 months.
*p<0.05 vs. mice receiving no initiator or promoter.
DEHP was given twice weekly after a single dose of
DMBA (20 ,ug).
In Vitro Studies Using JB6 Mouse
Epidermal Cells
JB6 cells lines Cl41, C121, and R219 were used to in-
vestigate the promoting ability of DEHP; the Cl41 cell
line was utilized to determine the promoting ability of
MEHP and EH. Cell cultures were grown in monolayer
culture in Eagle's Minimum Essential Medium (EMEM)
containing 8% fetal calf serum (FCS) and antibiotics as
described earlier(11). Mediumwasreplaced once aweek.
JB6 cells were passaged after dissociation with 0.06%
trypsin solution, and cultures were always maintained
below confluence. JB6 cells were suspended in culture
medium containing 0.33% Difco agar at a temperature
less than 40°C to which solvent alone, or stock solutions
of DEHP (1.3-51.2 x 10' M in acetone), MEHP (1-5
x 10-5 M in DMSO), or EH (4-77 x 10-4 M in DMSO)
had been added. Concentrations of MEHP were limited
by the toxicity of this compound. The suspension of 1.5
mL, containing 104 cells and 1.5 ,iL of test solution per
60 mm Petri dish, was layered over 0.5% agar base.
Assays were carried out in duplicate at 10% FCS con-
centrations. Colonies were counted at 14 days as de-
scribed previously (11).
FIGURE 1. Liverof B6C3F1 mousegiven DEHPat 12,000 ppmfor4months and afterinjectionoftritiatedthymidine. Hy
nuclear pleomorphism, eosinophilia ofhepatocyte cytoplasm, mitotic figure (m), labeling ofhepatocyte nuclei (arrowhea
H&E, x 330.
rtrophyofhepatocytes,
)andovalcells(arrows).
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Results
Toxicity of DEHP in Male B6C3F1 Mice
Mice given DEHP suffered obvious toxicity, including
a dose-related depression of body weight gain. Death
within 3 days after dosing was seen in 4/50 (8%) to 5/20
25
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FIGURE 2. Influence of DEHP on hepatocyte replication in livers of
male B6C3F1 mice. Mean ± standard error.
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(25%) of the mice that received one intragastric dose of
DEHP at 50 g/kg, but not in those that received a dose
of 25 g/kg (0/70). Lesions found by histologic examina-
tions in dead mice included hepatic lipidosis. Mice that
received DEHP at 12,000 ppm in the diet weighed only
one-half as much as controls by 16 weeks (6). Mean body
weight in mice that received 3000 and 6000 ppm DEHP
was depressed 10% to 20% by 24 weeks. Death occurred
from chronic DEHP ingestion only among mice that re-
ceived 12,000 ppm (Table 1).
Mice sacrificed at 2, 4, 6, 8, 10, or 18 months and those
that died between 1 and 18 months had several types of
hepatic lesions induced by DEHP Severity ofhepatic le-
sions was roughly proportional to increased liver weight
as a percentage of body weight. Marked eosinophilia of
hepatocyte cytoplasm, increased hepatocyte size, mitotic
figures (Figs. 1 and 2), oval cell hyperplasia, and pig-
mented macrophages were seen in mice that received
12,000 ppm DEHP Quantitative ultrastructural analysis
of liver sections revealed differences in organelles be-
tween mice given DEHP and those given PB (Figs 3a,
3b). These included increased peroxisomes in hepato-
cytes of mice given DEHP, and increased smooth endo-
plasmic reticulum in nonneoplastic hepatocytes of mice
given PB. Cell and cytoplasmic cross-sectional areas
were significantly increased inmice that received DEHP
(Table2). Themitoticindex wasdose andtime-associated
(Fig. 2). After 4 months ofDEHP exposure, hepatocyte
labelingindicesafterinjectionoftritiatedthymidine were
as follows (labeled nuclei per 1,000 hepatocytes + SE):
control, 0; DEHP, 12,000, 2.4 + 1.5; DEHP, 6,000, 0.4
+ 0.2; DEHP 3,000, 1.8 + 1.1; PB, 0. Oval cells in areas
of oval cell hyperplasia were also labeled (Fig. 1). Ne-
' 100 RER
Z-E
am 80 SER
D DEH60 -
ET 40
=0u
20-
Control DEHP DEN, DEN, DEN, DEN,
DEHP DEHP PB PB
Tumor Tumor
FIGURE 3. Quantitative ultrastructural analysis of cellular organedes in male B6C3F1 mice injected with DEN (80 mg/kg) at 4 weeks of age
and/or given either DEHP in the diet (12,000 ppm) for 6-8 months or PB in drinking water (500 ppm) for 8 months. For each lesion, 100-200
electron micrographs were evaluated using area analysis, point count analysis, and stereology. Mean ± standard deviation; RER, rough
endoplasmic reticulum; SER, smooth endoplasmic reticulum.
Table 2. Image analysis ofhepatocyte cell area, nuclear area, and nuclear/cytoplasmic ratio in B6C3F1 mice exposed to DEHP for 8
months.
Group Cell area, Am' Nuclear area, p.m' Cytoplasmic area t.m2 Nuclear/cytoplasmic ratio
Control 523.6 ± 198.5 79.0 ± 28.6 444.6 ± 169.9 0.18
DEHP (12,000 ppm) 1065.9 ± 280.9* 119.3 ± 36.2 946.7 ± 244.7* 0.13
'Mean ± standard deviation.
*p<0.01 compared with controls.
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Table 3. Tumor-initiating activity of DEHP in male B6C3F1 mice.a
Treatment 6 months 18 months
Hepatocellular
Initiator (g/kg) Promoter (ppm) FHPL (%)b FHPL/cm2 FHPL (%)b carcinoma (%)
DEHP (50) None 1/10 (10) 0.04 ± 0.03 2/7 (28) 0/7 (0)
DEHP (50) PB (500) 0/10 (0) 0 14/15 (93) 2/15 (13)
DEHP (25) None 0/10 (0) 0 4/10 (40) 1/10 (10)
DEHP (25) PB (500) 0/10 (0) 0 19/20 (95) 2/20 (10)
None PB 0/10 (0) 0 13/17 (76) 3/17 (17)
None None 0/10 (0) 0 0/10 (0) 0/10 (0)
aMale B6C3F1 mice, 4 weeks of age, were given one intragastric dose of DEHP at 50 or 25 g/kg. Two weeks later they were given PB at
500 ppm in drinking water, which was continued for 6 or 18 months.
bNumber of mice with lesion/number of mice in group.
crosis of single hepatocytes was seen only after several
months of exposure at the highest dosage level.
Renal lesions included tubular degeneration, necrosis
and regeneration with cystic hyperplasia. Renal tubular
lesions were dose- and time-related. They were severe
enough in mice given 12,000 ppm to contribute to ill
health and death after 6 months. In mice injected with
tritiated thymidine, regenerative tubular cells were la-
beled. Degeneration of testicular seminiferous tubules
was seen early in mice that received the highest dose,
but only at 18 months in some mice that received 6000
ppm. No lesions were seen inthyroid orpituitary glands.
Liver Tumor Initiation and Carcinogenesis
by DEHP in Mice
There was no evidence of liver tumor initiation by
DEHP after 6 or 18 months of subsequent exposure to
the liver tumor promoter, PB. A slight, but not signifi-
cant, increased incidence ofFHPL was seen at 18months
(Table 3). Focal hepatocellular proliferative lesions
(FHPL) including tumors were, however, found in some
mice after a single intragastric dose of DEHP or contin-
uous dietary exposure for up to 18 months while no tu-
mors or FHPL were found in untreated control mice (Ta-
ble 3). PB, by itself, caused a high incidence of FHPL
by 18 months. Among these FHPL, many foci were com-
posed of clear cells while adenomas were composed of
clear and eosinophilic hepatocytes.
Liver Tumor Promotion by DEHP and PB
in Mice
Both DEHP and PB were effective tumor promoters
(Table 1, Fig. 4). The FHPL in DEN-initiated mice that
received DEHP at 12,000 ppm were significantly larger
in mean focus volume at 6 months than those of mice in
other groups (Fig. 4). Histologically, these FHPL had
increased cell size and more numerous mitotic figures
and appeared more potentially malignant than those in
mice ofother groups, especially the group that received
DEN alone (Figs. 5-7). Hepatocellular carcinomas arose
within adenomas (Fig. 8) and replaced much ofthe liver
(Fig. 9). By 18 months, 25% ofthe mice given 6000 ppm
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FIGURE 4. Focal hepatocellular proliferative lesions in groups of 10
male B6C3F1 mice injected at 4 weeks of age with DEN (80 mg/
kg) and 2 weeks later given dietary DEHP (12,000 or 6000 ppm)
or PB (500 ppm) in water for up to 6 months. Mean ± standard
error.
DEHP had hepatocellular carcinoma metastatic to the
lung. Promoted FHPL, most commonly adenomas and
carcinomas, contained hepatocytes with immunoreactive
ax-fetoprotein (Fig. 10). Eleven of 23 hepatocellular neo-
plasms (8/12 adenomas, 3/11 carcinomas) in mice that
received DEHP or PB after DEN injection were readily
transplantable to the mammary fat pad of weanling
B6C3F1 mice, appearing at an average of 5.4 months
after transplantation. FHPL promoted by DEHP were
histologically basophilic (Fig. 4) and ultrastructurally
had abundant cytoplasmic rough endoplasmic reticulum,
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FIGURE 5. Small focalhepatocelularproliferative lesioncomposed ofhepatocytes with basophilic and clearcytoplasm. Mouse injected with DEN
and sacrificed at 6 months. H&E, x330.
FIGURE 6. Pbrtion ofhepatocellular adenoma with basophilic and clear hepatocytes in solid pattern in mouse injected with DEN. H&E, x 130.
FIGURE 7. Pbrtion ofhepatocellular adenoma composed oflarge basophilic hepatocytes forming single cell plates and with mitotic figures, in a
mouse given a single injection of DEN followed by DEHP (12,000 pm) for 10 months. H&E, x 54.
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FIGURE 8. Hepatocellular
H&E, x54.
followed by DEHP (6000 ppm) for 18 months.
FIGURE 9. Hepatocellular adenomas and carcinom in the liver of a mouse injected with DEN at 4 weeks of age and then fed diet containing
DEHP for 8 months.
FIGURE 10. Avidin-biotin peroxidase complex immunocytochemistry showinga-fetoprotein in ahepatocellular adenoma ofa mouse injected with
DEN (80 mg/kg) at 4 weeks of age and then fed diet containing DEHP (12,000 ppm) for 10 months. Hematoxylin, x330.
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FIGURE 11. Eosinophilic focal hepatocellular prolifrtive lesions an cytomegaly in the liver ofa mouse
with PB, beginning 2 weeks later and continuing for 6 months. H&E, x 130.
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FIGURE 12. Focal hepatocellular proliferative lesions (FHPL) in male B6C3F1 mice injected at 4 weeks of age with DEN (80 mg/kg) and then
given DEHP (3000 ppm) in the diet or PB (500 ppm) in the water for 1, 7, 28, 84 or 168 days. An additional group was maintained for an
additional 84 days without exposure to DEHP or PB. Lesions include hyperplastic foci, adenomas and carcinomas: (A) Percentage with
FHPL. (B) Lesions per cm2 ± standard error and mean area oflesions ± standard error.
while those promoted by PB were composed of eosino-
philic hepatocytes (Fig. 11) and had abundant cyto-
plasmic smooth endoplasmic reticulum (Fig. 3b). DEHP
was an effective liver tumor promoter after 28, 84, and
168 days while PB was effective only after 168 days of
exposure (Figs. 12a, 12b). At 84 days after termination
ofthe mostprolonged period ofexposure (168days), how-
ever, FHPL in mice given either PB or DEHP had not
regressed and in fact had increased in size.
Lung tumors were induced by DEN in all groups of
mice. The incidence of these tumors appeared not to be
affected by subsequent exposure to either DEHP or PB
(7). A few squamous cell carcinomas of the forestomach
and a few hepatoblastomas were found in DEN-exposed
FHPL 8
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Table 4. Effectiveness of hepatocellular tumor promoters on
unusual tumors of mice injected with DEN or given DEHP
intragastrically 18 months previously.a
Treatment Forestomach
Promoter papilloma or Liver
Initiator (mg/kg) (ppm) carcinoma hepatoblastoma
DEN (80) None 1/10 0/10
DEN (80) DEHP (6000) 1/20 2/20
DEN (80) DEHP (3000) 3/10 0/10
DEHP (50,000) PB (500) 1/15 0/15
DEN (80) PB (500) 0/20 5/20
None PB (500) 0/17 0/17
None None 0/10 0/10
aMaleB6C3F1 mice, 4weeks ofage, wereinjected intraperitoneally
with DEN in tricaprylin at a dosage of 80 mg/kg. DEHP was given
intragastrically at 50 g/kg. Two weeks later promoter exposure was
started. Lesions were not seen in mice of other groups.
mice; neither of these neoplasms were significantly af-
fected by DEHP or PB (Table 4).
Liver Tumor Promotion in F344/NCr
Rats
Both standard hematoxylin/eosin histology and histo-
chemical staining for gamma glutamyl transpeptidase
were used to identify FHPL in liver sections from DEN-
initiated rats. DEHP failed to increase the number or
size ofFHPL detected by eithermethod in rat liver after
16weeks, while PB was significantlyeffective atthe same
doses used in mice (Fig. 13). Liver weights were higher
(6% ofbody weight) in rats that received DEHP than in
controls (3.9%). The FHPL in DEN and DEN-DEHP
rats were morphologically similar and composed ofclear
cells, while those that received PB were composed of
hepatocytes witheosinophilic, clearand/orvacuolated cy-
toplasm. Hepatocytes in livers of rats treated with
DEHP were enlarged and contained prominent eosino-
philic cytoplasm, evidence of peroxisomal proliferation.
Renal lesions were not seen in rats.
Skin Tumor Promotion in Mice
DEHP did not promote the development ofskin tumors
after DMBA initiation in CD-1 mice (Table 5) nor was it
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FIGURE 13. Focal hepatocellular proliferative lesions (FHPL) in fe-
male F344 rats after a single intraperitoneal injection of DEN (282
mg/kg) at 5 weeks of age followed by DEHP (12,000 ppm) or PB
(500 ppm) beginning 2 weeks later and continuing for 14 weeks.
Mean ± standard error.
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FIGURE 14. Skin tumor promoting activities of TPA, mezerein and
DEHP in female SENCAR mice. Methods given by Diwan (15).
Table 5. Two-stage carcinogenesis in CD-1 mice.a
Cumulative no. Cumulative
Cumulative Cumulative no. of mice with one percentage of Cumulative no.
Groups (30 total no. of ofpapillomas or more mice with ofmice with
mice/group) Treatment papillomas per mouse papillomas papillomas carcinomas
1 DEHP,DEHP 0 0 0 0 0
2 DEHP, TPA 12 0.40 6 20 0
3 DMBA,DEHP 0 0 0 0 0
4 DMBA, TPA 616 20.50 29 97 1
5 DEHP, acetone 0 0 0 0 0
6 Acetone, TPA 10 0.34 6 20 0
7 DMBA, acetone 2 0.07 2 7 0
8 Acetone, acetone 0 0 0 0 0
'Experiment terminated at 40 weeks.
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an initiator or complete skin carcinogen after 40 weeks
(15). In female SENCAR mice, however, DEHP was a
weak second-stage promoter and a weaker complete pro-
moter ofskin carcinogenesis (Fig. 14) (15). Mezerein was
a considerably stronger second-stage promoter.
Anchorage Independence Induced in Mouse
JB6 Cells
DEHPshowed activityforpromotion oftransformation
in three promotable (p+) JB6 clonal lines of mouse ep-
idermis-derived cells (Table 6) (15). These lines of JB6
cells, including C141, Cl21, and R219, have previously been
shown to be promoted by anchorage independence and
tumorigenicity by tumor promoting phorbol esters, and
alsobymezerein, benzoylperoxideand epidermalgrowth
factor (11). Ofthe three cell lines used, Cl41 showed the
Table 6. Anchorage independence induced in mouse JB6-clone 41
cells.'
Concentration in medium, Colonies per 104
Chemical moles/Lb cells seeded
DEHP (MW 390.5) 0 48
1.3 xlO-6 912
2.6 xlO-6 1,104
13 xlO-6 2,268
26 x10_6 3,144
51 xlO-6 2,820
MEHP (MW 278.3) 1 xlo-8 134
2 xlO-8 336
3 xlO-8 480
4 x10-8 348
5 x10-8 288
EH (MW 130.2) 4 x10-7 48
8 x10-7 96
38 xlO-7 48
77 xlO-7 60
aColony counts wereperformed 14 days after cultures in soft agar
were prepared.
bStock solutions of each compound in acetone (DEHP) or DMSO
(MEHP, EH) were prepared at 1000 times the concentrations listed.
A volume of5 FxL was added to 4.5 mL ofcell suspension in soft agar
medium, thus diluting the stock solution by a factor of 1000 to the
final concentration listed in the table.
most pronounced maximum response to DEHP; nearly
32% of cells gave rise to colonies in 10% serum medium
in the presence of DEHP at a final concentration of 2.6
x 10' M. MEHP, a major hydrolysis product ofDEHP,
was much more toxic than the parent compound and con-
centrations above 6 x 108 M were found toxic to JB6
cells. MEHP concentrations shown to be effective for
promotion ranged from 2 to 5 x i0-8 M (Table 6). How-
ever, 2-ethylhexanol (EH), a second hydrolysis product
of DEHP, failed to promote transformation (Table 6).
Discussion
In our studies, DEHP was shown to be a promoter of
hepatocellular tumors initiated by DEN in mice; a sec-
ond-stage skin tumor promoter and a weak complete skin
tumor promoter in SENCAR mouse skin after DMBA
initiation; and also an inducer ofanchorage independence
in promotable mouse epidermis-derived JB6 cells. No in-
itiating activity was demonstrated in mouse liver al-
though a single intragastric exposure and continuous di-
etary exposure to DEHP led to an increased incidence
ofliver tumors in mice at 18 months in comparison with
untreated controls. Although the number of mice at 18
months was small, the findings are compatible with NTP
carcinogenesis studies (4).
The possible mechanism(s) of tumor promotion by
DEHP is (are) unknown. It has been suggested that
peroxisome proliferators as a group may be carcinogenic
by a nongenotoxic mechanism (3,16). The inhibition of
hepatictumorigenesis bytheantioxidantsethoxyquinand
2(3)-tert-butyl-4-hydroxyanisole (17) and other recent
studies have provided some evidence for the role of free
oxygen radicals and lipid peroxidation in carcinogenesis
by these compounds. Recent work, however, suggests
that this mechanism does not apply to DEHP (5).
Tumor promotion may result from effects on cellular
membranes and/or stimulation of proliferation of cells,
including hepatocytes, after exposure to an initiating
dose of carcinogen. DEHP has been shown by us and
others to produce hepatomegaly, in part due to liver cell
Table 7. Detection of focal hepatocellular proliferative lesions in male B6C3F1 mice.
% with FHPL (% with adenomas or carcinomas)
Initiator Promoter 2 months 6 months 18 months
DEN x la None 0 20(3) 90(80)
DEN x 1 DEHP x 1b 0 0 NDC
DEN x 1 DEHP x 28b 0 45(20) ND
DEN x 1 DEHP continuousd 0 90(50) 100(100)
None DEHP continuousd 0 10(10) 30(30)
DEHP x le None 0 10(10) 28(0)
None None 0 0 0
DEN x 1 PB continuousf 20 (0) 100(100) 100(100)
None PB continuousf 0 0 76(58)
'DEN (80mg/kg) was injected intraperitoneally once at 4 weeks of age.
b3000 ppm in the diet for 1 or 28 days.
'Not done.
d6000 ppm in the diet.
e50 g/kg by gavage once at 4 weeks of age.
f500 ppm in drinkdng water.
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FIGURE 15. Incidence offocal hepatocellular proliferative lesions (FHPL), including hyperplastic foci, hepatocellular adenomas and carcinomas,
as a function ofduration of exposure to a tumor promoter. DEN (80 mg/kg) was given intraperitoneally at 4 weeks of age as an initiator. DEHP
(6000 ppm) or PB (500 ppm) was then given, beginning 2 weeks later and continuing for up to 18 months. The fraction ofmice with FHPL is
dependent on the duration of exposure to the promoter. I, initiator; P promoter.
hyperplasia (3). Cell proliferation often has been quoted
as an important requirement for tumor promotion, al-
though recent studies have demonstrated that liver cell
replication per se is not a requirement for tumor pro-
motion by at least some specific chemicals that promote,
such as orotic acid (18-20). However, much of the hepa-
tomegaly induced by DEHP and by other hepatic per-
oxisomal proliferators appears to be a consequence of
increased size ofparenchymal cells. Because DEHP and
nafenopin cause peroxisome proliferation in rats but do
not cause tumor promotion in rat liver (21,22) under con-
ditions identical to those that in mice cause both per-
oxisome proliferation and tumor promotion, peroxisome
proliferation maynotbe animportantfactorin livertumor
promotion by DEHP in mice. On the other hand, the
demonstration of DEHP as a second-stage skin tumor
promoter(15) andtheincreasedhepatic focusgrowthrate
and mitotic figure in FHPL in mice given DEHP suggest
that liver cell replication can play some role in successful
tumor promotion by DEHP Although DEHP may share
some biological effects with other mouse skin tumor pro-
moters including TPA and mezerein, it has recently been
shown (P M. Blumberg, unpublished observations) that
any transforming activity in JB6 mouse epidermal cells
is not related to the phorbol ester receptor (23).
The morphology and biology of liver tumors initiated
by DEN in mice were dependent on the subsequent pro-
moter (6). DEHP promoted basophilic FHPL that ap-
peared to grow faster and/or appear sooner in the ex-
periment in mice given the highest dose of DEHP
Basophilic adenomas developed from these foci and tra-
becular carcinomas appeared within the adenomas. The
carcinomas metastaszized to the lungs in 10 to 25% ofthe
mice. In contrast, eosinophilic FHPL developed in mice
receiving PB after DEN. These foci enlarged slowly to
form adenomas and finally carcinomas, some of which
metastasized to the lungs. As noted previously, the pro-
moter may have affected directly the morphology and
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biologyoftumorcellsininduced tumors (6). The evidence
for this included the early appearance of basophilic and
clear-cell FHPL which resembled those in mice given
DEN alone. After these typical foci appeared, DEHP
seemed to affect the morphology and mitotic rate ofthe
cells in the FHPL. It is suggested that DEHP increased
replication of initiated hepatocytes that appeared mor-
phologically normal and hepatocytes in FHPL that were
already morphologically hyperplastic. Thus, the mito-
genic effect ofDEHP may play an important role in liver
tumor promotion (3,24). The lack ofsimilareffects on rat
liver foci initiated by DEN remains unexplained. It is
also possible that DEHP or PB promoted different ini-
tiated cell populations in mouse liver, and that as a con-
sequence the morphological and biological properties of
FHPL varied for these two liver promoters.
Tumor promotion has been defined by many authors
as a reversible process caused by chronic exposure to
certain agents, chemicals which are not genotoxic carcin-
ogens but which enhance the appearance, 'growth, and
development of initiated cells or tumors (8-10). These
processeshavebeenbestdescribedinskinandliver. More
recent studies have shown that reversibility, in part, de-
pends on the specific chemical and on the duration of
exposure. Quantitative estimation of tumors or preneo-
plastic lesions in mice given initiators or promoters also
varies with the dosage given and on the time ofsacrifice,
and depends on the method of evaluation (Table 7 and
Fig. 15). Our recent studies with DEHP provide addi-
tional evidence that tumor promotion can be irreversible
if exposure time is sufficient. Although classical pro-
moters, themselves, lack genotoxic activity and strong
carcinogenic potential, they almost always cause an in-
creased incidence oftumors in a target organ oftoxicity
PB and DEHP caused increased incidences of focal he-
patocellular proliferative lesions including neoplasms in
chronic studies that continued up to 2 years and in which
chronic nonneoplastic hepatotoxicity was marked (4).
Additional studies are in process in our laboratory on
the mechanism oftumor promotion by DEHP
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